PCI Pharma Services has started operations at its recently acquired site near Dublin, Ireland, and premiered its new contained packaging facility for the primary and secondary packaging of highly potent products.
An outsourcing services provider, PCI is deemed a global leader in the manufacturing of highly potent molecules at its purpose-built, contained manufacturing facility located at its Tredegar site in Wales, UK.
The company added the EU-based packaging site in October last year when it acquired Millmount Healthcare, a pharmaceutical and healthcare contract packaging services provider, to target European growth and mitigate against uncertainty brought about by Brexit. This is PCI’s fourth acquisition outside the US in the past four years.
“We are very excited to officially launch our state-of-the-art high contained packaging facility here in Ireland,” commented Bill Mitchell, PCI president and CEO. “The recent acquisition of Millmount Healthcare and further investment in this newest specialised facility adds considerable capacity and capability to our global supply network, enabling us to meet our customers’ ever-changing and evolving needs in many different geographies.”
Mitchell added: “The Republic of Ireland has a thriving pharmaceutical and biotech community, which PCI has been fortunate to support for many years. We have already received a tremendous response to the acquisition, and investments such as this high containment packaging facility are part of our strategic plan to continue business growth and service development for our customers. PCI is proud to provide services for medicines destined to over 100 countries around the world, and the Dublin site itself to more than 50 countries.”
Since the acquisition of Millmount Healthcare, PCI has added approximately 30 positions at the Dublin area facilities and anticipates adding more than 100 positions over the next five years as the sites continue to expand and grow its operations.